Q1 FY2020
Financial Results

January 30, 2020

AmerisourceBergen®



Cautionary Note Regarding Forward-Looking Statements

Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as "expect," "likely," "outlook," "forecast," "would," "could," "should," "can," "project," "intend," "plan," "continue," "sustain," "synergy," "on track," "believe," "seek," "estimate," "anticipate," "may," "possible," "assume," variations of such words, and similar expressions are intended to identify such forward-looking statements. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. These statements are not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. Among the factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory environment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical supply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or supplier payment terms; risks associated with the strategic, longterm relationship between Walgreens Boots Alliance, Inc. and the Company, including principally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; regulatory or enforcement action in connection with the production, labeling or packaging of products compounded by our compounded sterile preparations (CSP) business or the related consent decree; managing foreign expansion, including non-compliance with the U.S. Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the Company's operations; the impairment of goodwill or other intangible assets (including the impairments at PharMEDium and any additional impairments with respect to foreign operations), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company's business generally. Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2019 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.

GAAP / non-GAAP Reconciliation

In an effort to provide additional and useful information regarding AmerisourceBergen's financial results and other financial information as determined by generally accepted accounting principles (GAAP), certain materials presented during this event include non-GAAP information. A reconciliation of that information to GAAP and other related information is available in the supplemental material attached as an appendix to this presentation and posted on our website, investor.amerisourcebergen.com.



AmerisourceBergen is united in our responsibility to create healthier futures.

AmerisourceBergen drives innovative partnerships with global manufacturers, providers and pharmacies to improve product access and efficiency throughout the healthcare supply chain.

Q1 FY2020 Financial Results: Overview

AmerisourceBergen Delivered Strong Results

- Strong performance and execution across AmerisourceBergen's businesses - both Pharmaceutical Distribution and Global Commercialization Services and Animal Health groups delivered year-over-year growth, benefiting both overall revenue and adjusted EPS

Updated Guidance

- Updated fiscal year 2020 financial guidance reflects this strong performance, opportunistic share repurchases and the exit of the PharMEDium business

PharMEDium Update

- In late January 2020, the Company decided to exit the PharMEDium compounding business due to various factors, including, but not limited to, ongoing operational, regulatory and commercial challenges

Q1 FY2020 Financial Results

	GAAP	Adjusted (non-GAAP)[1]
Revenue *% Change (Year-over-Year)*	$47.9B 5.4%	$47.9B 5.4%
Gross Profit *% Change*	$1.2B (5.1)%	$1.2B 3.3%
Operating Expenses *% Change*	$968M 18.1%	$748M 2.3%
Operating Income *% Change*	$263M (44.9)%	$495M 5.0%
Interest Expense, Net *% Change*	$31M (26.5)%	$31M (26.5)%
Effective Tax Rate	18.7%	21.0%
Net Income Attributable to ABC *% Change*	$188M (52.3)%	$365M 6.4%
Diluted Earnings Per Share *% Change*	$0.90 (51.1)%	$1.76 10.0%
Diluted Shares Outstanding *% Change*	208M (3.0)%	208M (3.0)%

[1]See tables at end of presentation for GAAP to non-GAAP reconciliations

Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of the exhibit to the Company’s most recent Current Report on Form 8-K furnished under Item 2.02.

AmerisourceBergen®

Q1 FY2020 Financial Results: Pharmaceutical Distribution Services Segment

	Q1 FY2020	Q1 FY2019
Revenue	$46.0B	$43.7B
Operating Income	$391.7M	$373.2M
Percentages of Revenue		
Gross Profit	1.94%	2.01%
Operating Expenses	1.09%	1.16%
Operating Income	0.85%	0.85%

- Revenue increase primarily due to continued strong specialty product sales and increased volume associated with the growth of some of our largest customers
- Operating income increase primarily due to the increase in gross profit resulting from the growth in revenue

Q1 FY2020 Financial Results:
Other – Global Commercialization Services & Animal Health

	Q1 FY2020	Q1 FY2019
Revenue	$1.8B	$1.7B
Operating Income	$104.5M	$98.9M
Percentages of Revenue		
Gross Profit	19.01%	19.45%
Operating Expenses	13.35%	13.53%
Operating Income	5.66%	5.92%

- Other includes MWI, World Courier and AmerisourceBergen Consulting Services
- Revenue increase primarily due to growth across the group
- Operating income increase primarily due to the performance of ABCS and World Courier

Differentiated and positioned for growth

Customer Base

- *Key anchor customers*
- *Fast growing*
- *U.S. Pharmaceutical focus*



Innovative Services & Solutions

- *Customer-focused offerings serving manufacturers and provider customers*



Leadership in Specialty Distribution & Services

- *History of investment*
- *Largest footprint*
- *Comprehensive offering*



Successful Corporate Stewardship

- *Focus on value creation*
- *Financial: cash flow and capital allocation*
- *People: Advancing talent and culture*



AmerisourceBergen®

FY20 Financial Guidance

Expectations on an Adjusted (non-GAAP) Basis	
Revenue	Mid- to high-single digit percent growth
Diluted Earnings Per Share	***$7.55 to $7.80***
Operating Expense	Mid-single digit percent growth
Operating Income	***Mid-single digit* percent growth**
Pharmaceutical Distribution Services Operating Income	***Mid-single digit* percent growth**
Global Commercialization Services & Animal Health Operating Income	High-single digit percent growth
Effective Tax Rate	21% to 22%
Diluted weighted shares outstanding	***~208M***
Free Cash Flow	~$1.5B
Capital Expenditures	~$400M

(1) ***Bold, italicized numbers indicate updates to FY2020 financial guidance***

The Company does not provide forward-looking guidance on a GAAP basis as certain information, the probable significance of which cannot be determined, is not available and cannot be reasonably estimated. Please refer to the exhibit to the Company's most recent Current Report on Form 8-K furnished under Item 2.02 for more information.

AmerisourceBergen®

Appendix

AmerisourceBergen®

Appendix

AMERISOURCEBERGEN CORPORATION
GAAP TO NON-GAAP RECONCILIATIONS
(in thousands, except per share data)
(unaudited)

	Three Months Ended December 31, 2019							
	Gross Profit	Operating Expenses	Operating Income	Income Before Income Taxes	Income Tax Expense	Net Loss Attributable to Noncontrolling Interest	Net Income Attributable to ABC	Diluted Earnings Per Share
GAAP	$ 1,231,214	$ 967,777	$ 263,437	$ 229,588	$ 43,020	$ 1,072	$ 187,640	$ 0.90
Gain from antitrust litigation settlements	(8,492)	—	(8,492)	(8,492)	(1,974)	—	(6,518)	(0.03)
LIFO expense	13,281	—	13,281	13,281	3,087	—	10,194	0.05
PharMEDium remediation costs	7,135	(9,030)	16,165	16,165	3,757	—	12,408	0.06
Acquisition-related intangibles amortization	—	(33,566)	33,566	33,566	7,801	(436)	25,329	0.12
Employee severance, litigation, and other	—	(39,309)	39,309	39,309	9,136	—	30,173	0.15
Impairment of long-lived assets	—	(138,000)	138,000	138,000	32,071	—	105,929	0.51
Adjusted Non-GAAP	$ 1,243,138	$ 747,872	$ 495,266	$ 461,417	$ 96,898	$ 636	$ 365,155	$ 1.76
Adjusted Non-GAAP % change vs. prior year period	3.3%	2.3%	5.0%	8.2%	14.1%		6.4%	10.0%

Percentages of Revenue:	GAAP	Adjusted Non-GAAP
Gross profit	2.57%	2.60%
Operating expenses	2.02%	1.56%
Operating income	0.55%	1.03%

Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of the exhibit to the Company’s most recent Current Report on Form 8-K furnished under Item 2.02.

AmerisourceBergen®

Appendix

AMERISOURCEBERGEN CORPORATION
GAAP TO NON-GAAP RECONCILIATIONS
(in thousands, except per share data)
(unaudited)

	Three Months Ended December 31, 2018							
	Gross Profit	Operating Expenses	Operating Income	Income Before Income Taxes	Income Tax Expense	Net Loss Attributable to Noncontrolling Interest	Net Income Attributable to ABC	Diluted Earnings Per Share
GAAP	$ 1,297,580	$ 819,757	$ 477,823	$ 432,556	$ 40,803	$ 1,899	$ 393,652	$ 1.84
Gain from antitrust litigation settlements	(87,279)	—	(87,279)	(87,279)	(18,470)	—	(68,809)	(0.32)
LIFO credit	(3,029)	—	(3,029)	(3,029)	(641)	—	(2,388)	(0.01)
PharMEDium remediation costs	17,911	(2,584)	20,495	20,495	4,337	—	16,158	0.08
New York State Opioid Stewardship Act	(22,000)	—	(22,000)	(22,000)	(4,656)	—	(17,344)	(0.08)
Acquisition-related intangibles amortization	—	(45,152)	45,152	45,152	9,555	(506)	35,091	0.16
Employee severance, litigation, and other	—	(40,672)	40,672	40,672	16,980	—	23,692	0.11
Tax Reform [1]	—	—	—	—	36,997	—	(36,997)	(0.17)
Adjusted Non-GAAP	$ 1,203,183	$ 731,349	$ 471,834	$ 426,567	$ 84,905	$ 1,393	$ 343,055	$ 1.60 [2]

Percentages of Revenue:	GAAP	Adjusted Non-GAAP
Gross profit	2.86%	2.65%
Operating expenses	1.81%	1.61%
Operating income	1.05%	1.04%

[1] Amount represents the final measurement period adjustment to the one-time transition tax on historical foreign earnings and profits through December 31, 2017.

[2] The sum of the components does not equal the total due to rounding.

Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of the exhibit to the Company’s most recent Current Report on Form 8-K furnished under Item 2.02.

AmerisourceBergen®



Where knowledge,
reach and partnership
shape healthcare delivery.